Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Nagarajah

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
European Journal of Nuclear Medicine and Molecular Imaging|March 7, 2012
Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patientsC Riegger, J Herrmann, J Nagarajah, et al.
Cardiovascular and Interventional Radiology|August 25, 2019
<sup>68</sup>Ga-PSMA-PET/CT and Diffusion MRI Targeting for Cone-Beam CT-Guided Bone Biopsies of Castration-Resistant Prostate Cancer PatientsT R F van Steenbergen, M Smits, T W J Scheenen, et al.
British Journal of Cancer|January 18, 2014
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumorsS Bauer, R A Hilger, T Mühlenberg, et al.
Nuklearmedizin. Nuclear Medicine|February 17, 2015
[Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1)]T D Poeppel, C Boy, A Bockisch, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 13, 2021
PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reportsM J M Uijen, Y H W Derks, R I J Merkx, et al.
Nuklearmedizin. Nuclear Medicine|March 15, 2018
[Somatostatin receptor PET/CT (SSTR-PET/CT)]C Boy, T Poeppel, J Kotzerke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2024
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trialS van Wilpe, I S H Kloots, P H J Slootbeek, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
European Journal of Nuclear Medicine and Molecular Imaging|March 7, 2012
Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patientsC Riegger, J Herrmann, J Nagarajah, et al.
Cardiovascular and Interventional Radiology|August 25, 2019
<sup>68</sup>Ga-PSMA-PET/CT and Diffusion MRI Targeting for Cone-Beam CT-Guided Bone Biopsies of Castration-Resistant Prostate Cancer PatientsT R F van Steenbergen, M Smits, T W J Scheenen, et al.
British Journal of Cancer|January 18, 2014
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumorsS Bauer, R A Hilger, T Mühlenberg, et al.
Nuklearmedizin. Nuclear Medicine|February 17, 2015
[Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1)]T D Poeppel, C Boy, A Bockisch, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 13, 2021
PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reportsM J M Uijen, Y H W Derks, R I J Merkx, et al.
Nuklearmedizin. Nuclear Medicine|March 15, 2018
[Somatostatin receptor PET/CT (SSTR-PET/CT)]C Boy, T Poeppel, J Kotzerke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2024
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trialS van Wilpe, I S H Kloots, P H J Slootbeek, et al.
Pageof 2